COVID-19 Clinical Forum
Topics
Meeting category
Date(s)
17 Sep 2024
Important dates
September Edition
17 September 2024, at 20:00 CET / 14:00 EDT
Program Language
English
Meeting type
Virtual
Organizer

COVID-19 Clinical Forum 2024

Related Enduring Materials

General
What's New

About this Program

The COVID-19 Clinical Forum 2024 is a series of 2 online interactive meetings (90 minutes each) that provide continuing education to a wide range of healthcare professionals, including infectious disease doctors, pulmonologists, and virologists.

The program encompasses a broad range of topics, from COVID-19 epidemiology, treatments, post-COVID conditions & clinical manifestations, clinical management, pathophysiology, prevention, vaccines, to diagnostics and public health strategies.

This program is continuously updated as new information emerges and provides the latest COVID-19 data from renowned experts to clinicians worldwide. The program is designed to provide state-of-the-art, concise, and comprehensive lectures, and to facilitate participation from healthcare professionals from around the world.

Program Directors
General Information 
Topics of Interest
The program will encompass a wide range of topics, from vaccine research, immune response, SARS CoV-2 infection, diagnostics, and the use of artificial intelligence to contain the spread of the virus, to clinically orientated lectures on emerging treatment options and novel insights into disease pathophysiology.

The series will include continuous updates on COVID-19 infection control, epidemiology, prevention, diagnosis, pathogenesis, pathophysiology, clinical manifestations and management, emerging variants, therapeutic options, vaccine development and Implementation, public health measures, and treatments.
Who Should Attend?
-Healthcare providers;
-Infectious disease clinicians;
-Clinical virologists;
-Primary care physicians;
-Intensivists;
-Researchers;
-Nurses;
-Pharmacists;
-Others interested in staying informed on new insights and developments.
Learning Objectives
After participating in this activity, participants will be able to:

- Describe therapeutic options for the treatment of COVID-19
- Interpret clinical data on the use of Nirmatrelvir/Ritonavir for the treatment of long COVID
- Understand the impact of SARS-CoV-2 infection during pregnancy on mother and child health
Practical Information 
Schedule
-Tuesday, 19 March 2024 at 20:00 CET / 14:00 EST
-Tuesday, 17 September 2024 at 20:00 CEST / 14:00 EDT
Certificate of Attendance
A digital certificate of attendance will be sent to participants that have successfully completed the program and post-meeting survey.
Language
The official language of the webinar is English. Translation will not be provided.
Liability & Insurance
By registering for the webinar, participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Registration

Registration for the September 2024 Edition is now open! 

Login details on how to attend the next virtual program will be communicated one day before the session. A reminder will also be sent one hour before the session.

Fees and Conditions - September 2024 Edition

Regular Delegates* 

Industry Delegates**

Standard Fee 

Complimentary

€295

* The "Regular Delegate" category includes the following:

  • Healthcare professionals and patient representatives;
  • NGOs, activists, and lobbyists;
  • Government officials, representatives, and policymakers;
  • Researchers; and
  • Students in a relevant field.

Healthcare professionals are defined as professionals that provide any type of health care service to patients living with COVID-19 or other diseases. If you are not sure, please do not hesitate to contact us at catherine.phan@amededu.com.

**Fees apply to representatives from industry, medical education providers, investment companies, and others not listed above.

Industry representatives may receive complimentary virtual participation registration slots based on the level of support provided to the event. For more support and registration information, please contact us at catherine.phan@amededu.com.

Important
  • Please note that for for industry representatives, payment by credit card is required to be able to register for the webinar. Please contact the conference secretariat if this is not possible for you.

  • Virology Education reserves the right to cancel improper registrations. Claims for a refund will not be honoured.

  • Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full payment has been received and a confirmation of your registration has been sent.

Cancellation Policy - September Edition
In case of cancellation, the following refunds are applicable:

- Cancellation before/on 17 August 2024: 50% refund (minus an administration fee of €40)

- Cancellation after 17 August 2024: Unfortunately, no refund will be given

If you are unable to attend the conference, a substitute delegate is always welcome at no extra charge, provided that a letter of authorization from the original participant has been received and the conference secretariat has been notified of the name of the substitute delegate before 5 March 2024. A statement (email/letter) of cancellation must be sent to Virology Education.
Liability and Insurance
By registering for the conference, participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop. In case of cancellation of the meeting due to unforeseen circumstances, Virology Education cannot be held responsible for expenses made for travel, accommodation, visa applications, etc.
Program

The COVID-19 Clinical Forum 2024 - September Edition program is currently under development and subject to change.

The program of the COVID-19 Clinical Forum 2024 - March Edition can be found here: https://academicmedicaleducation.com/meeting/covid-19-clinical-forum-2024?tab=4

Previous Edition

The presentation videos and slides for speakers’ lectures are made available, provided that they have granted us permission to do so.

Tuesday, 19 March -
Update on COVID-19 Therapeutics
Daniel Kuritzkes, MD
Brigham and Women's Hospital / Harvard Medical School, United States
Nirmatrelvir/Ritonavir and Long Covid: Where are we Now?
Priscilla Hsue, MD
University of California, San Francisco; Zuckerberg San Francisco General Hospital, United States
COVID-19 in the Pregnancy and Postpartum Period
Emily Smith, ScD, MPH
The George Washington University, United States
Support

The COVID-19 Clinical Forum 2024 is supported by a grant from MSD. MSD has had no input into the selection of speakers or the content of the materials and presentations.

Support Our Initiative

Financial backing helps us deliver an impactful meeting experience to the benefit of healthcare professionals and researchers interested in COVID-19.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.

To show your commitment to the cause, get in touch with us for a tailored
support package by contacting Ting-Wen Cheng at ting-wen.cheng@amededu.com.

Endorsers

The COVID-19 Clinical Forum 2024 webinar series is endorsed by the following organizations:

Accreditation
EACCME® Accreditation

EACCME

The COVID-19 Clinical Forum 2024, Virtual, Netherlands 19/03/2024 - 19/03/2024, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1.5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

CME Accreditation

An application for CME accreditation will be submitted to the European Accreditation Council for Continuing Medical Education (EACCME) for each edition.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Please note that CME accreditation is only provided for delegates that attend the event livestream and submit the post-meeting survey.

How can I receive a CME-accredited Certificate of Attendance?

In order to be eligible to receive a CME-accredited Certificate of Attendance, you must have followed the full program and complete the post-evaluation survey. Please check your junk/spam inbox if you cannot find the email containing your link to the survey. If you followed the program and did not receive an email with a link to the survey, please email us at Catherine.Phan@amededu.com.

​The post-evaluation survey will be online for 1 week after the livestream. Please complete the survey within this time in order to receive your CME-accredited Certificate of Attendance. Once the survey is closed, it cannot be reopened.

Previous Editions
Language
Ratings previous edition
Content is relevant to my practice
4.1
(182)
Content was free from commercial bias
4.2
(182)
Content was presented clearly​
5.0
(182)